Post by Terumo Pharmaceutical Solutions Division

4,507 followers

š—§š—µš—² š—™š˜‚š˜š˜‚š—æš—² š—¼š—³ š—–š——š— š—¢ š—£š—®š—æš˜š—»š—²š—æš˜€š—µš—¶š—½š˜€: š—œš—»š˜€š—¶š—“š—µš˜š˜€ š—³š—æš—¼š—ŗ š—™š˜‚š—·š—¶š˜š—® š—”š—¼š—æš—¶š˜š˜€š˜‚š—“š˜‚ We're pleased to launch the first video in a five-part interview series with Noritsugu Fujita, Group Executive Officer and President, Pharmaceutical Solutions, Medical Care Solutions Company, in conversation with Pharmaceutical-Technology. In this first instalment, Fujita discusses the major trends shaping the future of CDMO partnerships, including the growing complexity of new therapies and the volatility of global supply chains. šŸŽ¬ Watch the video and stay tuned for the next instalment in the series, coming next week. #TerumoPharmaceuticalSolutionsDivison #CDMO #LeadershipInsights #PharmaceuticalTechnology #SupplyChains

Post content

Video Content